Related Experiment Video
Updated: Jul 18, 2026

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
Published on: September 18, 2018
Chemotherapy of malaria
1Pharmaceuticals Division, Department PRPI-D, F. Hoffmann-La Roche, CH-4070 Basel, Switzerland. robert_g.ridley@roche.com
Abstract:
Clinical trials continue to provide evidence for the efficacy of semi-synthetic artemisinin derivatives and the novel fixed dose combination therapies Malarone, co-artemether and chlorproguanil-dapsone. Single agents under development include the 8-aminoquinoline etaquine, pyronaridine and azithromycin. Preclinical interest in synthetic endoperoxides and quinoline analogues remains high and a significant is also being made in natural product chemistry. Dihydrofolate reductase remains a molecular drug target of interest, whereas phospholipid metabolism represents a new approach. Genomic information is likely to produce many new drug targets for exploration in the coming decade.
Related Concept Videos
Symbiosis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cryptococcal Meningitis
Malaria
Anthelminthic Agents
Antiprotozoal Agents

